Effects of nurse telesupport on transition between specialized and primary care in diabetic patients: study protocol for a randomized controlled trial

Ana Marina Moreira1,3*, Roberta Marobin1, Dimitris Varvaki Rados1,2, Camila Bergonsi de Farias1, Sabrina Coelli1, Bárbara Luiza Bernardi1, Lívia de Almeida Faller2, Laura Ferraz dos Santos2, Ana Maria Matzenbacher2, Natan Katz2, Erno Harzheim2, Sandra Pinho Silveiro1 and TelessaudeRS2

Abstract

Background: According to the Global Diabetes Plan, a unified health system with preventive and educational strategies is essential to proper diabetes care and primary settings should be the main site of care. In Brazil, there is limited access to outpatient hospital diabetes services, while primary-care diabetes support is underutilized. Telemedicine can be a useful adjunct to support discharge of stable patients with type 2 diabetes to the primary care setting. In this paper, we present a randomized controlled trial (RCT) protocol designed to evaluate the effects of telehealth support for stable type 2 diabetes patients discharged from hospital outpatient diabetes clinics.

Methods: We designed a RCT. Patients with stable type 2 diabetes (glycated hemoglobin < 8%) considered eligible for discharge from specialized to primary care will be included. Those with uncontrolled ischemic heart disease, severe neuropathy, and stage IV/V nephropathy will be excluded. Enrolled patients will be randomized into two groups: follow-up supported by periodic phone calls by a nurse (intervention group) plus primary care or routine primary care only (control group). The intervention group will receive regular telephone calls (every three months for one year) and will have a toll-free number to call in case of questions about disease management. The main outcome measure is a comparison of glycemic control between groups (assessed by glycated hemoglobin) at one-year follow-up.

Discussion: We plan to evaluate the effectiveness of a telephone-based intervention on glycemic control in patients with type 2 diabetes followed by primary care teams. Telemedicine can be an important adjunct in type 2 diabetes management, improving patient education and knowledge about the disease. Furthermore, it can help the healthcare system by alleviating overload in specialized care settings and supporting the stewardship role of primary care.

Trial registration: Clinical Trials, NCT02768480. Registered on 29 April 2016.

Keywords: Type 2 diabetes mellitus, Phone calls, Telemedicine, Glycemic control
Background
According to the International Diabetes Federation (IDF), in 2015, the global prevalence of diabetes was 415 million adults. Over 14.3 million of these adults live in Brazil, making it the country with the fourth largest number of persons living with diabetes [1]. Due to this large population of patients, mostly affected by type 2 diabetes, no health system can be planned without coordinating between primary and specialized care. The Global Diabetes Plan suggests that diabetes management in primary care could be key to achieving glycemic control and preventing chronic complications [2].

Brazil has experienced major changes in how healthcare is provided in the last 20 years: a structured and coordinated health system was created and primary care was defined as the main setting of healthcare. Despite these changes, the population has limited access to primary care, which has little problem-solving capacity, and specialized clinics are overcrowded.

Since 2007, TelessaúdeRS – UFRGS, a multiple-intervention telemedicine project, has been supporting primary care providers to improve management of chronic diseases. Our experience shows that many unnecessary referrals can be avoided through teleconsultations and training of primary care teams [3, 4]. We plan to explore whether telehealth strategies can have similar positive effects on patients being discharged from specialized to primary care. For the present project, we specifically aim to assess the effects of a simple remote monitoring strategy for the transition of type 2 diabetes care from specialized to primary facilities. This report follows the guidelines provided in the SPIRIT Statement [5]. We presented a standardized checklist with recommended items of SPIRIT Statement (Additional file 1).

Methods

Study design and settings
This open-label randomized controlled trial will seek to evaluate the effects of patient-directed phone calls as a means of supporting the care of individuals discharged from an outpatient hospital-based tertiary care diabetes clinic to primary care. The study will be performed at an outpatient diabetes clinic at Hospital de Clínicas de Porto Alegre, an academic hospital in southern Brazil. This hospital is a TelessaúdeRS partner in offering support to primary care.

Eligibility criteria

Inclusion criteria
Patients eligible for the trial must comply with all of the following criteria at randomization: established diagnosis of type 2 diabetes; and HbA1c level < 8% (HPLC method).

All patients that meet the inclusion criteria above are able to enter in the randomization, regardless of the treatment in use to manage diabetes (diet, oral antihyperglycemic medication, or insulin). The research team will identify patients meeting the inclusion criteria.

Exclusion criteria
Patients with the following criteria will not be included in the study: stage IV or V nephropathy; uncontrolled ischemic heart disease; or severe autonomous or peripheral neuropathy.

Intervention

Study flowchart, procedures and evaluations are depicted in Figs. 1 and 2. All patients will receive an illustrated brochure with information about diabetes care and a standardized discharge document. The discharge note will be directed to the primary care team and will present the patient’s medical history, current type 2 diabetes care regimen, individualized glycemic target, and management plan. The TelessaúdeRS toll-free number will also be mentioned in the discharge note as a tool for helping primary care manage the patient.

Patients randomized to the intervention group will receive a toll-free number to call nurses who can review their treatment and address any questions about their diabetes care. In addition, they will receive quarterly calls from the nurse team to review topics on diabetes education and non-pharmacologic and pharmacologic treatment. In the phone calls, nurses will do educational interventions, reviewing therapy adherence, side effects, techniques of insulin application, diet adherence, foot care, frequency of physician visits, and will give advises about hypoglycemia. Due to national legal restrictions, no treatment adjustments will be performed; therefore, if medication adjustments are needed, patients will be oriented to consult with the primary care provider.

Patients randomized to the control group will be followed exclusively by the primary care team. These patients will also receive follow-up phone calls at the same times as the intervention group (at three, six, nine, and 12 months), but without any diabetes intervention. If necessary, in both groups, treatment adjustments will be performed by the primary care physician, regardless of telemedicine actions.

Outcomes

One year after enrollment, both groups will undergo a standardized evaluation of current diabetes management, health services support, and treatment adherence. All participants will also undergo blood and urine collection for laboratory assessment.

The primary outcome will be glycemic control measured by HbA1c. The following outcomes will also be evaluated: blood pressure control evaluation (after 5 min of seated rest); lipid control; number of severe hypoglycemia
episodes; antiplatelet and statin therapy; number of physician, nurse, and dietitian appointments; rate of referral to tertiary care; current satisfaction with diabetes management; emergency visits because of acute complications of diabetes; treatment adherence; new or worsening nephropathy and peripheral neuropathy; major cardiovascular events; and death.

Sample size
We calculated a sample of 63 participants in each treatment arm to identify a between-group difference of 1% in HbA1c after one year, considering a standard deviation of 2%, an alpha of 0.05, and a statistical power of 80%.

Recruitment
Study monitors will be responsible for identifying eligible patients at the time of discharge. After discharge, the research team will explain the study procedures and will invite eligible patients to join the study. After providing written informed consent, the patients will be randomized to the intervention (primary care with nurse-led telephone support) or control (primary care alone) groups. Patients will complete a standardized questionnaire and undergo clinical and laboratory assessment.

Randomization and participant allocation
The random number sequence will be generated online (via randomization.com), using a 1:1 ratio, with blocks of four and six patients. The researcher responsible for randomization will not be involved in patient recruitment or enrollment. No stratification method will be used. Patients will be allocated sequentially, using dark-brown sealed envelopes, which will be opened only after patients have provided consent and the first assessment has been performed.

Blinding
The study is not blinded for trial participants, care providers, or outcome assessors. Statistical analysis will be performed in blind fashion.

Data collection methods
Study personnel will collect baseline data with a standardized questionnaire. Blood pressure will be measured after a 5-min rest. Information about foot sensitivity, ophthalmologic evaluation, glycemic control (HbA1c, fasting glucose), renal function (creatinine, glomerular filtration rate [GFR], and albuminuria), and lipid profile will be obtained from medical records. Follow-up information will be collected with a standardized questionnaire by telephone quarterly to assess patient's participation and minimize follow-up dropouts. After the completion of the study, the final assessment will be performed with a standardized questionnaire. The questionnaires will evaluate the following: demographic, ethnic, and education level data; drug or alcohol use; treatment of diabetes; cardiovascular history; associated comorbidities; hospital admissions; and smoking status. Furthermore, the final questionnaire will evaluate the treatment satisfaction, emergency visits for a diabetes reason, rate of hypoglycemia, number of primary care visits to review diabetes, and rate of referrals to tertiary care. The Brief Medication Questionnaire will be used to assess adherence and comprehension of therapy on baseline and follow-up. Blood pressure, body weight, and height and foot exam will be performed and blood and urinary samples will be collected.

Statistical methods
Variables with normal distribution will be presented as means ± standard deviation; asymmetric variables will be presented as median and interquartile range. Categorical variables will be presented as total counts and percentages. Normal continuous variables will be compared with Student's t-test and categorical variables will be
compared with the chi-square test. No interim analysis is planned. Main outcomes will be presented both with intention-to-treat (all randomized patients) and per-protocol (patients who received at least one telephone contact) analyses. We will use Cox regression for outcome analysis.

Data monitoring and auditing
Due to the lack of expected harms and the nature of the intervention and outcomes, no data monitoring committee will be created. The study coordinator will perform constant auditing of data and study conduct, but no external auditing process is planned.

Harms
There are no expected harms to study participants, except risk of data violation. The investigators will mitigate this risk by codifying participants with an identification number. Although the intervention group is expected to be more adherent to treatment, systematic differences in diabetes management are not expected.

Discussion
Diabetes mellitus is a chronic condition associated with high mortality, reduced quality of life, and increased health cost. In particular, patients living in developing countries experience additional problems, such as poor support and limited access to healthcare services [6]. In this context, an integrated, multidisciplinary health system focused on prevention and education strategies is the key to provide adequate care to diabetic patients. Such integrated systems should focus on providing highly effective primary care, which should be able to treat the majority of diabetic patients, and refer only those with severe complications and refractory disease. Furthermore, clinical support through
telemedicine interventions could strengthen primary care and enhance its quality [7].

Brazil has an excessive number of referrals and large waiting lists for referral to specialized care, with waiting times of months to years. Moreover, specialized services are unable to meet the demand for care, which leads to overloading of endocrinology clinics with unnecessary visits.

Our study aims to explore if we can improve the performance of primary care by supporting patients in the transition from specialized to primary care through the use of telehealth services. We aim to include well-controlled patients (defined as HbA1c < 8%) who no longer benefit from specialized care to glycemic treatment adjustment. We expect to answer whether a periodic, systematic intervention focused on education and adherence can improve diabetes control and whether this strategy can support management, maintaining, or improving the treatment offered in primary care. We will explore an innovative strategy to optimize the transition of care, based on a tool that has proven benefit in diabetes management. As future intervention, if this intervention shows benefits to diabetic patients being discharged from specialized care, an economic assessment is planned to evaluate the costs of the intervention and to discuss with stakeholders the widespread implementation.

In one previous study of low-income urban adults, periodic phone calls had a superior effect on glycemic control compared to printed education material (control). After one year, a significant decrement in HbA1c was demonstrated in the intervention group (−0.23% ± 0.11% versus +0.13% ± 0.13%; p = 0.04), with a better effect in patients who received more calls [8]. Similar results were found in a larger sample with fewer phone calls [9]. As expected, patients with the worst baseline glycemic control had greater reductions in HbA1c.

On the other hand, a recent meta-analysis of five studies that compared phone-call intervention with usual care in patients with type 2 diabetes showed a non-significant decrement of HbA1c values in the intervention group (pooled mean difference, −0.38%; 95% confidence interval, −0.91 to 0.16) [10]. Thus, the role of periodic educational phone calls on glycemic control remains unclear, despite some evidence for improvement [11].

Despite such evidence of improved glycemic control, long-term studies are lacking. The current literature has no information about the effects of such interventions on chronic complications of diabetes, cardiovascular events, or mortality, and the majority of studies have employed follow-up periods between six months and one year. A future long-term evaluation of the aforementioned outcomes is important to analyze the effectiveness of this intervention and decide if it is indeed useful to improve primary care, considering the cost benefit.

In summary, we believe that telehealth can be a useful tool for diabetes management, facilitating patient self-management and the transition from specialized to primary care. The results of this study will help us define whether telephone nurse support should be made widely available as a tool to reduce overcrowding of specialized services.

**Trial status**
This study is currently recruiting participants. The recruitment started at June 2015 and is expected to end at June 2017.

**Additional file**

Additional file 1: SPIRIT Checklist: A standard checklist required for publication of study protocols. (DOC 122 kb)

**Abbreviations**
GFR: Glomerular filtration rate; HbA1c: Glycated hemoglobin; UFRGS: Universidade Federal do Rio Grande do Sul

**Acknowledgements**
We thank Verônica Guattini, Laura Azevedo, and Raisa Vieira for their assistance with data collection. Members of the Hospital de Clínicas de Porto Alegre Endocrinology Unit assisted in discussion of cases and inclusion criteria for recruitment.

**Funding**
The project is funded by Hospital de Clínicas de Porto Alegre – Fundo de Incentivo a Pesquisas e Eventos (HCPA/FPE) – reference number: 40212314300005327. The study protocol was submitted to external peer review by the funding body in the process of obtaining funding.

**Availability of data and materials**
Research files will be kept by the investigators in binders stored at the research office. Study data will be handled unidentified. Only the researchers responsible for analyses will have access to the final dataset; the sponsor will not have access to data. Following the main publication of this trial, we plan to provide the unidentified dataset to interested personnel by contacting the authors and informing them of the planned analyses, which will be evaluated by the lead investigator of the study. When available, we plan to submit the trial results to a peer-reviewed medical journal. The International Committee of Medical Journal Editors authorship criteria and the CONSORT Statement will be followed [12].

**Authors’ contributions**
AMSM: study design, data collection and analysis, manuscript writing, and final approval of the manuscript. RM: data collection and analysis, critical revision, and final approval of the manuscript. DVR: study design, data collection and analysis, manuscript writing, and final approval of the manuscript. CB: data collection and manuscript writing. SC: data collection. BLB: data collection. LAF: data collection and analysis, critical revision, and final approval of the manuscript. SPS: conception and design, critical revision, and final approval of the manuscript. All persons listed as authors have contributed to preparing and approved the manuscript and that International Committee of Medical Journal Editors (ICMJE) criteria for authorship have been met.
Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study protocol was evaluated and approved by the Institutional Review Board, Hospital de Clínicas de Porto Alegre (IRB: 150503). No amendments to this version of the protocol are planned; however, protocol modifications will be communicated and evaluated by the Institutional Review Board. A trained research interviewer will obtain written informed consent before randomization and after explaining the research procedures.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Post Graduate Program in Medical Sciences – Division of Endocrinology, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
2 Division of Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
3Serviço de Endocrinologia do Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, 4 andar, Porto Alegre, RS CEP 90035-903, Brazil.

Received: 12 January 2017 Accepted: 27 April 2017
Published online: 18 May 2017

References
1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels: International Diabetes Federation; 2015.
2. International Diabetes Federation. Global Diabetes Plan 2011-2021. Brussels: International Diabetes Federation; 2012.
3. Harzheim E, Goncalves MR, Umpierre RN, da Silva Siqueira AC, Katz N, Agostinho MR, et al. Telehealth in Rio Grande do Sul, Brazil: bridging the gaps. Telemed J E Health. 2016;22(11):1–7.
4. Ministério da Saúde/Governo Federal do Brasil. In: TelessaúdeRS. 2007. https://www.ufrgs.br/telessauders. Accessed 02 Oct 2016.
5. Chan WA, TetzlaffJM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
6. Mudalal U, Kim WC, Kirk K, Rouse CJ, Narayan KMV, Ali M. Are recommended standards for diabetes care met in Central and South America? A systematic review. Diabetes Res Clin Pract. 2013;100(3):306–29.
7. Monteiro Grendene G, Szczecinski Rodrigues A, Katz N, Harzheim E. Refining quality assessment of primary health care for endocrinology in Rio Grande do Sul, Brazil. Stud Health Technol Inform. 2015;216:990.
8. Walker EA, Shmukler C, Ullman R, Blanco E, Scollan-Kolopoulos M, Cohen HW. Results of a successful telephonic intervention to improve diabetes control in urban adults. Diabetes Care. 2011;342–7.
9. Chamany S, Walker EA, Schechter CB, Gonzalez JS, Davis NJ, Ortega FM, et al. Telephone intervention to improve diabetes control: a randomized trial in the New York City A1c registry. Am J Prev Med. 2015;49(6):832–41.
10. Suksumboon N, Poolsupa N, Ngee YL. Impact of phone call intervention on glycemic control in diabetes patients: a systematic review and metaanalysis of randomized, controlled trials. PLoS One. 2014;9(2):e89207.
11. Marcolino MS, Maia JS, Alkmim MBM, Boersma E, Ribeiro AL. Telemedicine application in the care of diabetes patients: systematic review and meta-analysis. PLoS One. 2013;8(11).
12. Mohr D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c3869.

Submit your next manuscript to BioMed Central and we will help you at every step:
- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit